CRISPR & Next-Generation Gene Editing

1. The Evolution of CRISPR Tools

The original CRISPR-Cas9 system revolutionized biology by allowing researchers to induce targeted double-strand breaks (DSBs). However, relying on the cell's error-prone non-homologous end joining (NHEJ) repair pathway often leads to unpredictable indels (insertions and deletions).

• Base Editing: Developed by David Liu's lab, base editors fuse a catalytically impaired Cas nuclease to a deaminase enzyme, allowing targeted C-to-T or A-to-G point mutations without inducing DSBs.
• Prime Editing: A more recent and versatile tool that uses a Cas9 nickase fused to a reverse transcriptase, programmed by a prime editing guide RNA (pegRNA), capable of mediating targeted insertions, deletions, and all 12 possible base-to-base conversions.

2. Clinical Pipeline & Milestones

The FDA approval of Casgevy (exagamglogene autotemcel) in late 2023 for sickle cell disease and transfusion-dependent beta-thalassemia marked a watershed moment. It proved that CRISPR therapies could clear rigorous safety and efficacy hurdles.

Therapy	Sponsor	Target / Indication	Status
Casgevy	Vertex / CRISPR Tx	BCL11A (Sickle Cell/TDT)	Approved (2023)
NTLA-2001	Intellia	ATTR Amyloidosis (In vivo)	Phase 3
VERVE-101	Verve Tx	PCSK9 (HeFH) - Base Editing	Phase 1b

3. Delivery Bottlenecks

The primary hurdle for in vivo editing remains delivery. Lipid Nanoparticles (LNPs) are effective for liver targets (as utilized by Intellia and Verve), but extrahepatic delivery (e.g., to muscle, brain, or bone marrow) requires significant advances in viral vectors (AAVs) or novel targeted non-viral platforms.